全文获取类型
收费全文 | 10937篇 |
免费 | 551篇 |
国内免费 | 91篇 |
专业分类
耳鼻咽喉 | 204篇 |
儿科学 | 171篇 |
妇产科学 | 139篇 |
基础医学 | 1396篇 |
口腔科学 | 388篇 |
临床医学 | 699篇 |
内科学 | 2791篇 |
皮肤病学 | 223篇 |
神经病学 | 826篇 |
特种医学 | 318篇 |
外科学 | 1763篇 |
综合类 | 33篇 |
预防医学 | 319篇 |
眼科学 | 198篇 |
药学 | 727篇 |
中国医学 | 33篇 |
肿瘤学 | 1351篇 |
出版年
2023年 | 62篇 |
2022年 | 45篇 |
2021年 | 197篇 |
2020年 | 114篇 |
2019年 | 148篇 |
2018年 | 172篇 |
2017年 | 164篇 |
2016年 | 192篇 |
2015年 | 185篇 |
2014年 | 233篇 |
2013年 | 316篇 |
2012年 | 580篇 |
2011年 | 587篇 |
2010年 | 299篇 |
2009年 | 285篇 |
2008年 | 484篇 |
2007年 | 535篇 |
2006年 | 536篇 |
2005年 | 557篇 |
2004年 | 511篇 |
2003年 | 497篇 |
2002年 | 493篇 |
2001年 | 369篇 |
2000年 | 406篇 |
1999年 | 373篇 |
1998年 | 131篇 |
1997年 | 95篇 |
1996年 | 108篇 |
1995年 | 86篇 |
1994年 | 87篇 |
1993年 | 76篇 |
1992年 | 279篇 |
1991年 | 217篇 |
1990年 | 207篇 |
1989年 | 199篇 |
1988年 | 197篇 |
1987年 | 190篇 |
1986年 | 192篇 |
1985年 | 160篇 |
1984年 | 117篇 |
1983年 | 95篇 |
1981年 | 48篇 |
1979年 | 83篇 |
1978年 | 59篇 |
1977年 | 45篇 |
1974年 | 63篇 |
1973年 | 44篇 |
1972年 | 49篇 |
1970年 | 47篇 |
1969年 | 58篇 |
排序方式: 共有10000条查询结果,搜索用时 147 毫秒
1.
Harada Hideyuki Omori Shota Mori Keita Konno Masahiro Murakami Haruyasu Imagumbai Toshiyuki Fukuda Haruyuki Nakamatsu Kiyoshi Kimura Tomoki Tanabe Hiroaki Fujita Hideki Tatebe Hitoshi Fujitaka Kazunori Nishimura Yasumasa 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(6):1025-1033
International Journal of Clinical Oncology - This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced... 相似文献
2.
Tomoya Kurokawa Takuya Nakagawa Keisuke Matsusaka Masaki Fukuyo Masato Mima Kiyoshi Misawa Bahityar Rahmutulla Jun‐ichiro Ikeda Toyoyuki Hanazawa Yoshitaka Okamoto Atsushi Kaneda 《Cancer science》2020,111(4):1407-1416
Irradiation, or chemoradiotherapy, is a curative treatment for oropharyngeal squamous cell carcinoma (OPSCC). Its invasiveness, however, can often negate its efficacy. Therefore, developing methods to predict which patients would benefit from irradiation is urgent. Promoter DNA hypermethylation was recently reported to correlate with favorable OPSCC prognosis. It is still unclear, however, whether there is an association between promoter DNA methylation and response to irradiation. In this study, we analyzed DNA methylation in the specimens from 40 OPSCC patients who had undergone irradiation, using the Infinium assay. Our results showed significant correlation between high levels of promoter DNA methylation and better response to treatment (P < 0.01). We used the 10 most differentially‐methylated genes between responders and non–responders to develop a panel of predictive markers for efficacy. Our panel had high sensitivity, specificity and accuracy (92%, 93% and 93%, respectively). We conducted pyrosequencing to quantitatively validate the methylation levels of 8 of the 10 marker genes (ROBO1, ULK4P3, MYOD1, LBX1, CACNA1A, IRX4, DPYSL3 and ELAVL2) obtained by Infinium. The validation by pyrosequencing showed that these 8 genes had a high prediction performance for the training set of 40 specimens and for a validation set of 35 OPSCC specimens, showing 96% sensitivity, 89% specificity and 94% accuracy. Methylation of these markers correlated significantly with better progression‐free and overall survival rates, regardless of human papillomavirus status. These results indicate that increased DNA methylation is associated with better responses to irradiation therapy and that DNA methylation can help establish efficacy prediction markers in OPSCC. 相似文献
3.
Hirokazu Miki Shingen Nakamura Masahiro Oura Hirofumi Hamano Kenji Ikuta Naoto Okada Yasunobu Okamoto Kimiko Sogabe Mamiko Takahashi Masami Iwasa Kengo Udaka Takeshi Harada Kiyoe Kurahashi Shiro Fujii Sumiko Yoshida Kumiko Kagawa Itsuro Endo Ken-ichi Aihara Masahiro Abe 《British journal of haematology》2019,186(2):355-358
4.
Eriko Yanagida Hiroaki Miyoshi Mai Takeuchi Noriaki Yoshida Kazutaka Nakashima Kyohei Yamada Takeshi Umeno Yasumasa Shimasaki Takuya Furuta Masao Seto Koichi Ohshima 《Hematological oncology》2020,38(5):680-688
The interaction of CD47 and signal-regulatory protein alpha (SIRPα) induces “don't eat me signal”, leading suppression of phagocytosis. This signal can affect the clinical course of malignant disease. Although CD47 and SIRPα expression are associated with clinicopathological features in several neoplasms, the investigation for adult T-cell leukemia/lymphoma (ATLL) has not been well-documented. This study aimed to declare the association between CD47 and SIRPα expression and clinicopathological features in ATLL. We performed immunostaining on 73 biopsy samples and found that CD47 is primarily expressed in tumor cells, while SIRPα is expressed in non-neoplastic stromal cells. CD47 positive cases showed significantly higher FoxP3 (P = .0232) and lower CCR4 (P = .0214). SIRPα positive cases presented significantly better overall survival than SIRPα negative cases (P = .0132). SIRPα positive cases showed significantly HLA class I (P = .0062), HLA class II (P = .0133), microenvironment PD-L1 (miPD-L1) (P = .0032), and FoxP3 (P = .0229) positivity. In univariate analysis, SIRPα expression was significantly related to prognosis (Hazard ratio [HR] 0.470; 95% confidence interval [CI] 0.253-0.870; P = .0167], although multivariate analysis did not show SIPRα as an independent prognostic factor. The expression of SIRPα on stromal cells reflects activated immune surveillance mechanism in tumor microenvironment and induce good prognosis in ATLL. More detailed studies for gene expression or genomic abnormalities will disclose clinical and biological significance of the CD47 and SIRPα in ATLL. 相似文献
5.
6.
Naoko Uetsu Yuki Nomura Yoshie Matsuyama Hiroyuki Okamoto 《The Journal of dermatology》2020,47(4):369-377
Solar urticaria has unique spectra, such as inhibition and augmentation. The clinical significance of these spectra, especially augmentation, is not well understood. Reported cases of solar urticaria with augmentation spectra are extremely rare in the published English-language work. The purposes of this study were to evaluate the clinical features of solar urticaria with augmentation spectra and to elucidate the mechanisms and clinical importance of the spectra. We experienced 11 cases (five females, six males; mean age, 40.1 years; range, 1–74) of solar urticaria with augmentation spectra from April 2007 to July 2019. Augmentation spectra were UV-B in three cases, UV-A in two, visible light in four, UV-A and UV-B in one, and UV-A and visible light in one. Augmentation spectra were observed before action spectra in four cases, after in six, and before and after in one. Injection of sera irradiated with action spectra and augmentation spectra in vitro induced stronger immediate reactions than those of only action spectrum-irradiated sera in four of five cases. The results of injection tests suggested that augmentation spectra enhance the production of urticaria-forming factor. Clinically, we observed severe urticarial reactions in four cases, including anaphylaxis in three and moderate urticarial reactions in three. These results suggest that augmentation spectra are not as rare as previously thought and that they are associated with the severity of solar urticaria. Therefore, phototesting for both augmentation and action spectra should be performed to provide appropriate guidance for patients with solar urticaria. 相似文献
7.
8.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
9.
Takuya Nakagawa Keisuke Matsusaka Kiyoshi Misawa Satoshi Ota Masaki Fukuyo Bahityar Rahmutulla Naoki Kunii Daiju Sakurai Toyoyuki Hanazawa Hisahiro Matsubara Yoshitaka Okamoto Atsushi Kaneda 《International journal of cancer. Journal international du cancer》2020,146(9):2460-2474
While the incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been increasing in these two decades, primarily due to human papillomavirus (HPV), stratification of OPSCC into molecular subgroups showing different clinicopathological features has not been fully investigated. We performed DNA methylome analysis using Infinium 450k for 170 OPSCC cases, including 89 cases in our cohort and 81 cases reported by The Cancer Genome Atlas, together with targeted exon sequencing analysis. We stratified OPSCC by hierarchical clustering analysis using methylome data. Methylation levels of classifier markers were validated quantitatively using pyrosequencing, and area under the curve (AUC) values of receiver operating characteristics (ROC) curves were calculated. OPSCC was stratified into four epigenotypes: HPV(+) high-methylation (OP1), HPV(+) intermediate-methylation (OP2), HPV(−) intermediate-methylation (OP3) and HPV(−) low-methylation (OP4). Ten methylation marker genes were generated: five to classify HPV(+) cases into OP1 and OP2, and five to classify HPV(−) cases into OP3 and OP4. AUC values of ROC curves were 0.969 and 0.952 for the two marker panels, respectively. While significantly higher TP53 mutation and CCND1 copy number gains were observed in HPV(−) than in HPV(+) groups (p < 0.01), no significant difference of genomic aberrations was observed between OP1 and OP2, or OP3 and OP4. The four epigenotypes showed significantly different prognosis (p = 0.0006), distinguishing the most favorable OPSCC subgroup (OP1) among generally favorable HPV(+) cases, and the most unfavorable OPSCC subgroup (OP3) among generally unfavorable HPV(−) cases. HPV(+) and HPV(−) OPSCC are further divided into distinct DNA methylation epigenotypes, showing significantly different prognosis. 相似文献
10.